🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06925204
Recruiting Observational

Natural Course and Therapeutic Effect of Chronic Pancreatitis

NCT06925204 · tracked via the Priya Life Science China tracker
Sponsor
Changhai Hospital
Phase
Observational
Started
2025-04-13
Last updated
2025-04-15

Condition(s) studied

Chronic Pancreatitis

Investigational drug(s) / intervention(s)

Observation

Observation: Based on the patient's specific clinical condition, the appropriate examination and treatment in accordance with the conventional diagnosis and treatment standards of CP will be performed, including but not limited to: CT, MRI, endoscopic ultrasound (EUS) with or without biopsy, endocrine hormone testing (such as oral glucose tolerance test or mixed meal tolerance testing), pancreatic exocrine function tests (such as fecal elastase-1 test), extracorporeal shock wave lithotripsy (ESWL), endoscopic retrograde cholangiopancreatography (ERCP), and pancreatic enzyme replacement therapy. Patients were followed up regularly.

Study summary

The goal of this observational study is to establish a prospective cohort of chronic pancreatitis (CP) patients to provide evidence-based guidance for clinical practice and comprehensively optimize diagnostic and treatment strategies. The study aims to collect detailed demographic information, clinical data, medical imaging, biological samples, and follow-up information from CP patients.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with chronic pancreatitis. Exclusion Criteria: * Patients who refuse to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Changhai Hospital Shanghai Shanghai Municipality Recruiting

More Changhai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06925204 on ClinicalTrials.gov ↗ ← All trials in China